Anish Suri is President & CSO at Cue Biopharma, Inc. (CUE). They have made 6 open-market trades across 1 company since 2018, most recently 2023-08-25.
CIK 0001739130
2 open-market purchases totalling $20K since 2018, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CUE | 135,638 | $2.3M |
Shares reported on the most recent Form 4, priced at the 2023-08-29 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CUE | BUY | 2023-08-25 | 2023-08-29 | $2.76 | $11K | -5.6% | -18.6% | -16.8% |
| CUE | SELL | 2021-11-15 | 2021-11-17 | $18.05 | $144K | -23.1% | -26.0% | -55.5% |
| CUE | SELL | 2021-11-11 | 2021-11-15 | $15.07 | $301K | -27.1% | -36.1% | -61.9% |
| CUE | SELL | 2021-09-23 | 2021-09-27 | $15.23 | $305K | -12.8% | -20.2% | -21.7% |
| CUE | SELL · 10b5-1 | 2020-08-05 | 2020-08-07 | $20.01 | $16K | +5.2% | -20.5% | -40.6% |
| CUE | SELL | 2020-08-03 | 2020-08-05 | $20.01 | $240K | +4.5% | -23.1% | -45.0% |
| CUE | BUY | 2018-12-21 | 2018-12-26 | $4.37 | $9K | +27.6% | +22.1% | +77.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.